Brief: Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD

Wave Life Sciences

26/03/2025 11:41

March 26 (Reuters) - WAVE Life Sciences Ltd WVE.O:

WAVE LIFE SCIENCES ANNOUNCES POSITIVE DATA FROM FORWARD-53 CLINICAL TRIAL IN DMD INCLUDING SIGNIFICANT FUNCTIONAL BENEFIT AND REVERSAL OF MUSCLE DAMAGE AFTER 48 WEEKS OF DOSING WITH WVE-N531

WAVE LIFE SCIENCES LTD - WVE-N531 SHOWS 3.8-SECOND IMPROVEMENT IN TIME-TO-RISE VERSUS. NATURAL HISTORY

WAVE LIFE SCIENCES LTD - WVE-N531 SHOWS SIGNIFICANT REDUCTION IN MUSCLE FIBROSIS

WAVE LIFE SCIENCES LTD - WVE-N531 SAFE AND WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS

WAVE LIFE SCIENCES LTD - TO FILE NDA FOR WVE-N531 IN 2026 FOR ACCELERATED APPROVAL

WAVE LIFE SCIENCES LTD: WVE-N531 REMAINS SAFE AND WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS

WAVE LIFE SCIENCES LTD - TO FILE CTAS IN 2026 FOR MULTIPLE DMD CANDIDATES

Source text: ID:nGNX5PK42X

Further company coverage: WVE.O

 ((Reuters.Briefs@thomsonreuters.com;))